Achieve Life Sciences, Inc. has released its financial results for the third quarter of 2026 and announced a corporate rebranding to AchieveRx, The Quit Company. The company, which trades on the Nasdaq under the ticker symbol QUIT, reported cash, cash equivalents, and marketable securities totaling $201.5 million as of September 30, 2026. This figure represents an increase from $187.3 million at the end of the previous quarter, driven primarily by proceeds from the exercise of previously issued warrants.

For the three months ended September 30, 2026, the company reported total operating expenses of $20.5 million and a net loss of $12.1 million. Over the first nine months of the year, total operating expenses reached $49.4 million, resulting in a net loss of $97.0 million. The net loss for the third quarter included a non-cash gain of $6.9 million related to the change in fair value of warrant liabilities issued during the second quarter of 2026.

On the business front, AchieveRx has completed the transition of finished drug product manufacturing for its investigational compound cytisinicline to U.S.-based Adare Pharma Solutions. The company completed the production of three commercial-scale stability batches at Adare’s facility. The resubmission of the New Drug Application (NDA) for cytisinicline remains on track for the fourth quarter of 2026. The company anticipates potential FDA approval by the end of the second quarter of 2027, with a U.S. commercial launch to follow, if approved.

In clinical news, AchieveRx presented 52-week results from its long-term, open-label ORCA-OL trial at the CHEST 2026 Annual Meeting. The trial enrolled 479 adults who had previously failed to quit smoking or vaping. The data showed that quit rates rose over the course of treatment, from 25.5% at Weeks 9–12 to 31.2% at Weeks 49–52. At the end of the 52-week treatment period, 39.4% of participants new to cytisinicline had quit, as had 27.8% of those who had taken the drug in a prior trial.

The company has also strengthened its leadership team with two senior appointments: Ben Halladay as Chief Financial Officer and Kaitlyn Tuson as Senior Vice President of Marketing and Communications. Additionally, the company has introduced a new corporate brand identity reflecting its shift toward a commercial-stage company.